{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,28]],"date-time":"2025-11-28T12:39:32Z","timestamp":1764333572962,"version":"3.44.0"},"reference-count":11,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"7","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,10]]},"abstract":"<jats:p>As of December 2022, calaspargase-pegol is the standard long-acting asparaginase formulation for patients younger than 22 years of age with acute leukemia. This 3-year retrospective evaluation compared real-world safety and efficacy of calaspargase-pegol versus pegaspargase in pediatric patients. Incidence and severity of hypersensitivity reactions, silent inactivation, and common asparaginase-associated adverse effects were collected. A total of 103 patients were included, of whom 50 received calaspargase-pegol and 58 received pegaspargase. Similar rates of symptomatic hypersensitivity reactions (20% vs. 10.3%; <jats:italic toggle=\"yes\">P<\/jats:italic>=0.16) and silent inactivation (16% vs. 5.2%; <jats:italic toggle=\"yes\">P<\/jats:italic>=0.18) were seen with calaspargase-pegol versus pegaspargase, respectively. However, 13 patients in the calaspargase-pegol group required conversion to short-acting asparaginase compared with 6 patients in the pegaspargase group (26% vs. 10.3%; <jats:italic toggle=\"yes\">P<\/jats:italic>=0.03). Most adverse effects were comparable between the 2 groups, except for a lower rate of hyperbilirubinemia with calaspargase-pegol compared with pegaspargase (34% vs. 58.6%; <jats:italic toggle=\"yes\">P<\/jats:italic>=0.01). Overall, no significant differences were found between the formulations in terms of rate of hypersensitivity reactions and silent inactivation. However, calaspargase-pegol did require more conversions to short-acting asparaginase therapy. Additional monitoring and preventative measures should be utilized to prevent calaspargase-pegol\u2013associated adverse effects.<\/jats:p>","DOI":"10.1097\/mph.0000000000003098","type":"journal-article","created":{"date-parts":[[2025,8,22]],"date-time":"2025-08-22T13:01:24Z","timestamp":1755867684000},"page":"e305-e309","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":1,"title":["Comparing Tolerability and Toxicity of Calaspargase-Pegol and Pegaspargase in Pediatric Leukemia Patients"],"prefix":"10.1097","volume":"47","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0549-3129","authenticated-orcid":false,"given":"Jinjoo","family":"Kang","sequence":"first","affiliation":[{"name":"Pharmacy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9171-1681","authenticated-orcid":false,"given":"Srivarshini","family":"Kanukollu","sequence":"additional","affiliation":[{"name":"Pharmacy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Angelica","family":"Bevinetto","sequence":"additional","affiliation":[{"name":"Pharmacy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rosamarie","family":"Corless","sequence":"additional","affiliation":[{"name":"Division of Hematology\/Oncology and Cellular Therapy, Department of Pediatrics, Cohen Children's Medical Center, New Hyde Park"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Arlene","family":"Redner","sequence":"additional","affiliation":[{"name":"Division of Hematology\/Oncology and Cellular Therapy, Department of Pediatrics, Cohen Children's Medical Center, New Hyde Park"},{"name":"Department of Pediatrics, Zucker School of Medicine at Hofstra\/Northwell, Hempstead, NY."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","published-online":{"date-parts":[[2025,8,22]]},"reference":[{"key":"R1-20250925","doi-asserted-by":"crossref","first-page":"902117","DOI":"10.3389\/fped.2022.902117","article-title":"Current use of asparaginase in acute lymphoblastic leukemia\/lymphoblastic lymphoma","volume":"10","author":"Maese","year":"2022","journal-title":"Front Pediatr"},{"key":"R2-20250925","doi-asserted-by":"crossref","first-page":"e000977","DOI":"10.1136\/esmoopen-2020-000977","article-title":"Increasing completion of asparaginase treatment in childhood acute lymphoblastic leukaemia (ALL): summary of an expert panel discussion","volume":"5","author":"Baruchel","year":"2020","journal-title":"ESMO Open"},{"key":"R3-20250925","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/j.htct.2019.07.010","article-title":"Asparaginase: an old drug with new questions","volume":"42","author":"Cecconello","year":"2020","journal-title":"Hematol Transfus Cell Ther"},{"key":"R4-20250925","doi-asserted-by":"crossref","first-page":"3496","DOI":"10.1200\/JCO.20.03692","article-title":"Efficacy and toxicity of pegaspargase and calaspargase pegol in childhood acute lymphoblastic leukemia: results of DFCI 11-001","volume":"39","author":"Vrooman","year":"2021","journal-title":"J Clin Oncol"},{"key":"R5-20250925","doi-asserted-by":"crossref","first-page":"3874","DOI":"10.1200\/JCO.2014.55.5763","article-title":"Pharmacokinetic and pharmacodynamic properties of calaspargase pegol Escherichia coli L-asparaginase in the treatment of patients with acute lymphoblastic leukemia: results from Children\u2019s Oncology Group Study AALL07P4","volume":"32","author":"Angiolillo","year":"2014","journal-title":"J Clin Oncol"},{"issue":"Supplement 1","key":"R7-20250925","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1182\/blood-2023-187694","article-title":"A real-world, single institution, post-market comparison of pegaspargase and calasparagase pegol-mknl therapeutic drug monitoring and toxicity","volume":"142","author":"Spear","year":"2023","journal-title":"Blood"},{"key":"R9-20250925","doi-asserted-by":"crossref","first-page":"e27797","DOI":"10.1002\/pbc.27797","article-title":"Universal premedication and therapeutic drug monitoring for asparaginase-based therapy prevents infusion-associated acute adverse events and drug substitutions","volume":"66","author":"Cooper","year":"2019","journal-title":"Pediatr Blood Cancer"},{"key":"R10-20250925","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.2217\/fon-2021-1288","article-title":"Hypersensitivity reactions to asparaginase therapy in acute lymphoblastic leukemia: immunology and clinical consequences","volume":"18","author":"Burke","year":"2022","journal-title":"Future Oncol"},{"key":"R12-20250925","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1080\/10428194.2023.2282950","article-title":"Attempted desensitization to calaspargase pegol: a familiar approach to a new problem","volume":"65","author":"Kuhn","year":"2024","journal-title":"Leuk Lymphoma"},{"key":"R13-20250925","doi-asserted-by":"crossref","first-page":"e30891","DOI":"10.1002\/pbc.30891","article-title":"Desensitization using pegaspargase in the era of commercially available Erwinia: a single-institution report on efficacy, cost, and resource utilization","volume":"71","author":"Feldman","year":"2024","journal-title":"Pediatr Blood Cancer"},{"key":"R14-20250925","doi-asserted-by":"crossref","first-page":"2360","DOI":"10.1080\/10428194.2018.1435873","article-title":"Levocarnitine for asparaginase-induced hepatic injury: a multi-institutional case series and review of the literature","volume":"59","author":"Schulte","year":"2018","journal-title":"Leuk Lymphoma"}],"container-title":["Journal of Pediatric Hematology\/Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MPH.0000000000003098","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T12:00:59Z","timestamp":1758801659000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MPH.0000000000003098"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,22]]},"references-count":11,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.1097\/mph.0000000000003098","relation":{},"ISSN":["1077-4114","1536-3678"],"issn-type":[{"type":"print","value":"1077-4114"},{"type":"electronic","value":"1536-3678"}],"subject":[],"published":{"date-parts":[[2025,8,22]]},"assertion":[{"value":"2025-02-14","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-06-29","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}